Alumis Inc. - Common Stock (ALMS)

9.4700
+0.00 (0.00%)
NASDAQ· Last Trade: Sep 2nd, 9:20 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close9.470
Open-
Bid9.890
Ask9.950
Day's RangeN/A - N/A
52 Week Range3.760 - 31.35
Volume236,464
Market Cap509.03M
PE Ratio (TTM)-4.047
EPS (TTM)-2.3
Dividend & YieldN/A (N/A)
1 Month Average Volume2,109,224

Chart

About Alumis Inc. - Common Stock (ALMS)

Alumis Inc. is a cutting-edge technology company specializing in the development and commercialization of innovative solutions within the healthcare sector. Focused on enhancing patient care and operational efficiencies, the company harnesses advanced data analytics and artificial intelligence to provide healthcare providers with actionable insights and tools. Their offerings aim to improve patient outcomes, streamline workflows, and reduce costs, positioning Alumis as a key player in the transformation of healthcare services. Through their commitment to research and development, the company strives to address the evolving needs of the medical community and empower healthcare professionals with the resources necessary for excellence in care delivery. Read More

News & Press Releases

Here are the top movers in Tuesday's session.chartmill.com
Via Chartmill · September 1, 2026
What's going on in today's sessionchartmill.com
Via Chartmill · September 1, 2026
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promisemarketbeat.com
Alumis (NASDAQ:ALMS) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients wi
Via MarketBeat · September 1, 2026
Tuesday's session: gap up and gap down stockschartmill.com
Via Chartmill · September 1, 2026
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarterfool.com
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Via The Motley Fool · May 24, 2026
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Sharesfool.com
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
Via The Motley Fool · May 19, 2026
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investorsfool.com
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Via The Motley Fool · May 19, 2026
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filingfool.com
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via The Motley Fool · May 18, 2026
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullishfool.com
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Via The Motley Fool · May 18, 2026
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarterfool.com
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Via The Motley Fool · May 17, 2026
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Backfool.com
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Via The Motley Fool · May 15, 2026
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drugfool.com
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Via The Motley Fool · May 10, 2026
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.fool.com
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Via The Motley Fool · February 3, 2026
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Millionfool.com
Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock gains.
Via The Motley Fool · January 17, 2026
On Thursday, there are stocks with unusual volume. Let's take a look.chartmill.com
Via Chartmill · January 8, 2026
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Todaystocktwits.com
Nvidia, Apple, Microsoft, and select biotech names dominated early market buzz.
Via Stocktwits · January 8, 2026
Unusual volume stocks in Wednesday's sessionchartmill.com
Via Chartmill · January 7, 2026
Nasdaq, S&P 500 Futures Tread Water Ahead Of ADP Data: Why NVDA, META, APLD, VTYX, ALMS Are On Traders' Radar Todaystocktwits.com
Via Stocktwits · January 7, 2026
Dow Clears 49,000 as AI’s “Data Deluge” Ignites a Memory-Stock Melt-Upchartmill.com
Via Chartmill · January 7, 2026
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potentialstocktwits.com
The company also disclosed plans of a $175 million underwritten share offering after releasing its Phase 3 trial data.
Via Stocktwits · January 6, 2026
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinibfool.com
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
Via The Motley Fool · January 6, 2026
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation," investors are pulling capital from the expensive, AI-saturated titans of the Nasdaq and pouring
Via MarketMinute · January 6, 2026
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session.chartmill.com
Via Chartmill · January 6, 2026
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
Synergy CHC Corp. (NASDAQ: SNYR) is gaining renewed investor attention as its FOCUSfactor® functional beverage platform scales rapidly through the Company’s already-established retail ecosystem—built on the strength of its 25-year FOCUSfactor® brain health supplement legacy . By leveraging long-standing national distribution relationships, Synergy is accelerating beverage adoption without the execution risk typically associated with launching a new consumer brand.This beverage expansion underpins Roth Capital Partners’ Buy rating and 12-month $7 price target on SNYR. Roth projects revenues could grow from approximately $35.4 million in 2025 to nearly $55 million in 2026, driven largely by beverage penetration layered onto Synergy’s existing retail and wholesale channels.
Via AB Newswire · January 6, 2026
Let's have a look at the top gainers and losers in the middle of the day of today's session.chartmill.com
Via Chartmill · January 6, 2026